Photostable Near-Infrared Dye

What makes the new near-infrared dye different?

Near-infrared fluorescence imaging allows surgeons to visualize selected tissues in real time after administering a fluorescent contrast agent. The Korean research highlighted by Medical Xpress focuses on photostability: the ability of a dye to continue emitting a detectable signal despite repeated or prolonged illumination. Conventional fluorophores can undergo photobleaching, a chemical change that progressively weakens their fluorescence.

A more stable signal could be valuable during lengthy operations or procedures requiring repeated inspection of the same anatomical area. It may also improve consistency when surgeons assess tissue perfusion, identify anatomical structures or define targeted tissue. However, brightness and photostability are only part of a useful imaging agent's profile; toxicity, tissue distribution, clearance and target specificity are also critical.

How could a photostable dye improve fluorescence-guided surgery?

Fluorescence-guided surgery adds molecular or physiological information to the surgeon's direct view. Indocyanine green, an established near-infrared agent, is used clinically for applications including vascular and tissue-perfusion assessment. Its usefulness demonstrates the advantages of near-infrared imaging, where light generally penetrates tissue more effectively than visible fluorescence and produces less interference from naturally occurring tissue signals.

If the new dye retains fluorescence for longer, it could reduce uncertainty caused by signal decay and potentially support extended imaging sessions. That possibility is especially relevant when anatomy must be reassessed after dissection or when perfusion changes during a procedure. Researchers will still need to determine whether the dye works with clinical cameras and whether its improved laboratory stability produces a meaningful surgical benefit.

What testing is needed before the dye can be used in patients?

New fluorescent agents must undergo extensive evaluation because they are administered to patients and may circulate through multiple organs. Preclinical studies typically examine acute and delayed toxicity, metabolism, elimination, dose-response behavior and whether fluorescent breakdown products create additional risks. Reliable manufacturing standards are also necessary to ensure that every batch has consistent purity and optical performance.

Human trials would then need to establish an appropriate dose and compare imaging performance with current methods. Clinically important outcomes may include signal durability, tissue contrast, diagnostic accuracy, adverse reactions and whether the information changes surgical decisions or patient outcomes. Until those data are available, the dye should be viewed as a promising imaging-platform development rather than a proven surgical treatment.